EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report

Epidermal growth factor receptor (EGFR) targeting tyrosine kinase inhibitors (TKIs) can result in significant skin toxicities that may impact patients’ quality of life. While these skin reactions are well documented in patients with lighter skin, there is a paucity of literature and images to guide...

Full description

Bibliographic Details
Main Authors: Arman Zereshkian, Alia Thawer, David M. Hwang, Susanna Cheng
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/29/4/205
Description
Summary:Epidermal growth factor receptor (EGFR) targeting tyrosine kinase inhibitors (TKIs) can result in significant skin toxicities that may impact patients’ quality of life. While these skin reactions are well documented in patients with lighter skin, there is a paucity of literature and images to guide clinicians in their assessment in patients with darker skin tones. Given that dermatological reactions in patients with darker skin are not well represented, this can result in the undertreatment or mistreatment of these otherwise common toxicities. Herein, we present a case of a female patient with a darker skin tone with metastatic non-small cell lung carcinoma (NSCLC) with EGFR-TKI-related skin toxicity and her clinical course.
ISSN:1198-0052
1718-7729